THE STUDY ADVANCE: RESULTS REQUIRING EXPLANATIONS

1. Adler A.I, Stratton I.M., Neil H.A, et al. Assotiation of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 2000;321:412-9.

2. UK Prospective Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998;317:703-13.

3. Hansson L., Zanchetti J.A., Carruthers S.G., et al.; HOT Study Group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998;351:1755-62.

4. American Diabetes Association. Standards of medical care in diabetes: 2006. Diabetes Care 2006;29(Suppl. 1):S4–S42.

5. Lenfant C, Chobanian AV, Jones DW, Roccella EJ; Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Seventh report of the Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7): resetting the hypertension sails. Hypertension 2003;41:1178–9.

6. Ryden L., Standl E., Bartnik M. et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 2007;28(1): 88-136.

7. Buse JB., Ginsberg HN., Bakris GL. et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Circulation 2007;115(1):114-26.

8. Barkis G.L., Weir M.R., DeQuattro V., McMahon F.G. Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy. Kidney Int 1998;54(4):1283-9.

9. Niskanen L, Hedner T, Hansson L, Lanke J, Niklason A. Reduced cardiovascular morbidity and mortality in hypertensive diabetic patients on first-line therapy with an ACE inhibitor compared with a diuretic / beta-blocker-based treatment regimen: a subanalysis of the Captopril Prevention Project. Diabetes Care 2001;24:2091-6.

10. Estacio RO, Jeffers BW, Hiatt WR, et al. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med 1998;338:645-52.

11. Tatti P, Pahor M, Byington RP, et al. Outcome results of the Fosinopril versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 1998;21:597-603.

12. Fressinaud P., Berrut G., Gallois H. Antihypertensive action, clinical and biological acceptability of perindopril: main results in 23,460 patients with mild to moderate hypertension treated for 6 months in general practice [in French]. Ann Cardiol Angeiol. 1993;42(1):51-9.

13. Gosse P., Sheridan DJ., Zannad F. et al. Regression of left ventricular hypertrophy in hypertensive patients treated with indapamide SR 1.5 mg versus enalapril 20 mg: the LIVE study. J Hypertens. 2000;18:1465-75.

14. Marre M, Garcia Puig J, Kokot F, et al. Effect of indapamide SR on microalbuminuria--the NESTOR study (Natrilix SR versus Enalapril Study in Type 2 diabetic hypertensives with micrOalbuminuRia)--rationale and protocol for the main trial. J Hypertens Suppl. 2003;21(1):S19-24.

15. PROGRESS Collaborative Group. Randomised trial of perindopril-based blood pressure lowering regimen among 6,105 individuals with previous stroke or transient ischemic attack. Lancet 2001;358:1033-41.

16. London G.M., Asmar R.G., O,Rourke M.F. et al., on behalf of the REASON Project Coordinators and ivestigators. Mechanism(s) of selective systolic blood pressure reduction after a low-dose combination of perindopril/indapamide in hypertensive subjects: comparison with atenolol. J Am Coll Cardiol. 2004;43:92-9.

17. Dahl f B., Gosse P., Gueret P. et al. Perindopril/indapamide combination more effective then enalapril in reducing blood pressure and left ventricular mass: the PICXEL study. J. Hypertens. 2005;23:2063-70.

18. Mourad J.J., Hanon O., Deverre J.R. et al. Improvement of impaired coronary vasodilator reserve in hypertensive patients by low-dose ACE inhibitor/diuretic therapy: a pilot PET study. J Renin Angiotensin Aldosterone Syst. 2003;4:94-5.

19. Lawes CM, Parag V, Bennett DA, et al.; Asia Pacific Cohort Studied Collaboration. Blood glucose and risk of cardiovascular disease in the Asia Pacific region. Diabetes Care 2004;27:2836-42.

20. Stratton I.M., Adler A.L., Neil H.A. et al. Association of glycemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405-12.

21. Stettler C., Allemann S., Juni P. et al. Glycaemic control and macrovascular disease in types 1 and 2 diabetes mellitus: meta-analysis of randomized trials. Am Heart J. 2006;152:27-38.

22. Patel A., ADVANCE Collaborative Group. Effects of fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomized controlled trial. Lancet.2007;370:829-840.